Literature DB >> 16841204

[Classical topical therapy of psoriasis].

S Gerdes1, U Mrowietz.   

Abstract

In most cases mild to moderate forms of psoriasis can be treated with topical therapy. In addition, topical agents are also routinely combined with UV or systemic therapy to treat severe forms of psoriasis. A variety of standard products are available. The oldest topical treatment is anthralin. Since 1952 the development of topical corticosteroids has revolutionized not only dermatological treatment in general but the treatment of psoriasis in particular. Through the continuous development of these compounds, a better risk-benefit profile has been achieved. Corticosteroids are the most frequently employed topical agent for psoriasis treatment worldwide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16841204     DOI: 10.1007/s00105-006-1186-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  12 in total

1.  Clobetasol under hydrocolloid occlusion in psoriasis results in a complete block of proliferation and in a rebound of lesions following discontinuation.

Authors:  J M Mommers; P E van Erp; P C van De Kerkhof
Journal:  Dermatology       Date:  1999       Impact factor: 5.366

2.  Circadian activity of topical 0.05% betamethasone dipropionate in human skin in vivo.

Authors:  L K Pershing; J L Corlett; L D Lambert; C E Poncelet
Journal:  J Invest Dermatol       Date:  1994-05       Impact factor: 8.551

3.  Intolerance and contact allergy to tar and dithranol in psoriasis.

Authors:  A D Burden; H Muston; M H Beck
Journal:  Contact Dermatitis       Date:  1994-09       Impact factor: 6.600

Review 4.  Tars and anthralins.

Authors:  A Silverman; A Menter; J L Hairston
Journal:  Dermatol Clin       Date:  1995-10       Impact factor: 3.478

5.  Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis.

Authors:  J J Miller; D Roling; D Margolis; C Guzzo
Journal:  J Am Acad Dermatol       Date:  1999-10       Impact factor: 11.527

6.  The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria.

Authors:  Alison McGill; Adrian Frank; Nicola Emmett; Douglas M Turnbull; Mark A Birch-Machin; Nick J Reynolds
Journal:  FASEB J       Date:  2005-03-31       Impact factor: 5.191

7.  Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils.

Authors:  J M Schröder; U Kosfeld; E Christophers
Journal:  J Invest Dermatol       Date:  1985-07       Impact factor: 8.551

8.  Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.

Authors:  H M Ockenfels; G Nussbaum; T Schultewolter; P M Burger; M Goos
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

9.  Down-regulation of epidermal growth factor receptors by dithranol.

Authors:  L Kemény; G Michel; P Arenberger; T Ruzicka
Journal:  Acta Derm Venereol       Date:  1993-02       Impact factor: 4.437

10.  Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro.

Authors:  A B Gottlieb; L Khandke; J F Krane; L Staiano-Coico; R Ashinoff; J G Krueger
Journal:  J Invest Dermatol       Date:  1992-05       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.